Crescent Biopharma (CBIO) Operating Income (2013 - 2026)

Crescent Biopharma (CBIO) has reported Operating Income for 14 consecutive years, with -$26.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Income fell 25.36% year-over-year to -$26.4 million in Q2 2026; TTM through Jun 2026 was -$168.5 million, a 164.56% decrease from a year earlier, with the FY2025 full-year figure at -$152.6 million, down 281.2% from the prior year.
• Operating Income was -$26.4 million for Q2 2026 at Crescent Biopharma, down from -$24.7 million in the prior quarter.
• Over five years, Operating Income peaked at -$8.8 million in Q3 2022 and troughed at -$91.5 million in Q4 2025.
• A 5-year average of -$18.9 million and a median of -$12.3 million in 2022 frame the typical range for Operating Income.
• Across the five-year window, Operating Income soared 49.43% in 2022 and tumbled 432.21% in 2025, its largest moves.
• Over 5 years, Operating Income stood at -$10.6 million in 2022, then rose by 9.71% to -$9.6 million in 2023, then slumped by 79.24% to -$17.2 million in 2024, then plunged by 432.21% to -$91.5 million in 2025, then soared by 71.18% to -$26.4 million in 2026.
• The last three Operating Income figures came in at -$26.4 million (Q2 2026), -$24.7 million (Q1 2026), and -$91.5 million (Q4 2025), per Business Quant data.